Moreover, newer GLP-1 receptor agonists have moved further away from the original venom peptide structure
"And that inflammatory state results in organ damage that leads to cardiometabolic disease, kidney disease, diabetes, certain forms of cancer, and potentially certain neurodegenerative changes," says Kessler
How Excellus BlueCross BlueShield (BCBS) helps employers manage this trend As the GLP-1 landscape evolves, we are dedicated to keeping our policies aligned with the latest data to ensure the best outcomes for your team
And weight gain is often driven by multiple factors: hormones, insulin resistance, medications, sleep deprivation, stress, and muscle loss
Conclusions Regarding the controversy of whether GLP-1based therapy can increase the risk for specific malignant disease like pancreatic carcinoma and thyroid cancer, our conclusion is that apparently there is neither firm evidence in favor of this hypothesis nor evidence strong enough to rule out any such increased risk based on results available at present
Based on Phase 2 clinical trials, patients with T2DM who were inadequately managed with diet and exercise alone or were on a stable metformin regimen for at least 3 months before screening received once-weekly subcutaneous injections of tirzepatide at doses of 1 mg, 5 mg, 10 mg, or 15 mg for 26 weeks
.png)
